Eli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.
Eli Lilly and Co.'s second-quarter earnings surpassed Wall Street estimates as sales of its blockbuster weight-loss drugs soared. "Mounjaro, Zepbound and Verzenio led our strong financial performance in the second quarter as we advanced our manufacturing expansion agenda," CEO David Ricks said in a statement. During the three-month period, Lilly notched $11.3 billion in global revenue, surpassing the $9.92 billion that Wall Street expected.
WEIGHT-LOSS MEDICATION SHORTAGE CREATES MARKET FOR BOGUS DRUGS Lilly's tirzepatide was first approved to treat Type 2 diabetes and sold under the brand name Mounjaro in 2022. In November 2023, federal officials approved the injection, sold under the brand name Zepbound, for adults with obesity or those who are overweight and also deal with weight-related medical issues such as hypertension, dyslipidemia or Type 2 diabetes mellitus.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
Read more »
Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA saysDemand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarThe success of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
Read more »
Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales SoarRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »